Drug Search Results
More Filters [+]

PDA-002

Alternative Names: pda-002, pda002, pda 002
Latest Update: 2024-03-20
Latest Update Note: News Article

Product Description

human placenta-derived cells for Peripheral Arterial Disease and Diabetic Foot Ulcer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01859117)

Mechanisms of Action: Immunomodulator

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intramuscular

FDA Designation: Orphan Drug - Muscular Dystrophies|Muscular Dystrophy, Facioscapulohumeral *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Celularity
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PDA-002

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peripheral Nervous System Diseases|Peripheral Arterial Disease|Peripheral Vascular Diseases|Diabetic Foot|Diabetic Nephropathy

Phase 1: Diabetic Foot|Peripheral Arterial Disease|Peripheral Vascular Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CCT-PDA-002-DFU-002

P2

Terminated

Peripheral Vascular Diseases|Peripheral Arterial Disease|Diabetic Foot

2018-02-28

24%

CCT-PDA-002-DFU-003

P2

Withdrawn

Diabetic Foot|Peripheral Vascular Diseases|Peripheral Arterial Disease

2017-09-01

CCT-PDA-002-DPN-001

P2

Completed

Diabetic Nephropathy|Peripheral Nervous System Diseases

2017-03-07

24%

CCT-PDA-002-DFU-001

P1

Completed

Peripheral Vascular Diseases|Diabetic Foot|Peripheral Arterial Disease

2016-10-01

22%

Recent News Events